Case Details
- Citation: [2022] SGHC 75
- Title: Mytsyk, Viktoriia v Med Travel Pte Ltd and another
- Court: High Court of the Republic of Singapore (General Division)
- Originating Summons: HC/OS 987/2021
- Date of Judgment: 31 March 2022
- Date(s) Heard: 13 January 2022, 25 February 2022
- Judge: Mavis Chionh Sze Chyi J
- Plaintiff/Applicant: Viktoriia Mytsyk (“Ms Mytsyk”)
- Defendants/Respondents: (1) Med Travel Pte Ltd (“Med Travel”) (2) Amunugama Anushka Bandara (“Mr Anushka”)
- Legal Area: Companies — statutory derivative action
- Statutory Framework: Companies Act (Cap 50, 2006 Rev Ed), s 216A (including s 216A(3)(b) and s 216A(3)(c))
- Legislation Referenced (as provided): Companies Act, Companies Act, Companies Act (s 216A)
- Judgment Length: 49 pages; 15,748 words
- Procedural Posture: Application for leave under s 216A to bring an action in the name and on behalf of the company against a director for alleged breaches of directors’ duties
- Representation: Ms Mytsyk represented by counsel; Mr Anushka acted in person
Summary
In Mytsyk, Viktoriia v Med Travel Pte Ltd and another [2022] SGHC 75, the High Court considered an application for leave to commence a statutory derivative action under s 216A of the Companies Act. The applicant, Ms Mytsyk, sought leave to bring proceedings in the name of Med Travel against its director, Mr Anushka, alleging multiple breaches of directors’ duties. The allegations included misappropriation of company funds, forgery of documents, causing the company to incur unaffordable debt through the purchase of a property, diversion of income, unlawful prevention of business, misuse of funds for personal expenses, and negligence leading to penalties for late GST submissions.
The dispute was closely intertwined with a broader family and corporate ownership controversy. Ms Mytsyk and Mr Anushka had previously been married and later became embroiled in divorce and related civil proceedings (notably HC/S 1247/2019). In that earlier suit, Ms Mytsyk and others sought declarations concerning the true legal and beneficial ownership of Med Travel and another company. Against that backdrop, Mr Anushka resisted the statutory derivative application, raising issues of locus standi and, more substantively, challenging whether the proposed derivative action satisfied the statutory requirements of good faith and whether it appeared prima facie to be in the interests of the company.
The court’s decision focused on the statutory gatekeeping function of s 216A. It examined whether the applicant had standing to bring the application, whether the application was brought in good faith, and whether the proposed action appeared prima facie to be in Med Travel’s interests. The judgment provides a detailed application of the principles governing statutory derivative actions in Singapore, particularly the evidential and evaluative thresholds embedded in s 216A(3)(b) and s 216A(3)(c).
What Were the Facts of This Case?
Ms Mytsyk and Mr Anushka were previously married and lived together for several years with children from both relationships. In August 2019, Ms Mytsyk commenced divorce proceedings. Shortly thereafter, she also initiated a civil suit against Mr Anushka and Med Travel, being HC/S 1247/2019 (“S 1247”). In S 1247, Mr Anushka was the first defendant and Med Travel the second defendant. Ms Mytsyk’s co-plaintiffs included her father, Mr Hryhorii Liaskovskyi (“Mr Liaskovskyi”), and a company, Health & Help Pte Ltd (“Health & Help”), in which Ms Mytsyk was the sole shareholder and director on record.
In S 1247, Ms Mytsyk and her co-plaintiffs sought, among other things, declarations that Mr Liaskovskyi was the true legal and beneficial owner of both Med Travel and Health & Help. The factual narrative in the present application was largely gleaned from the pleadings in S 1247, which were exhibited in Mr Anushka’s affidavit in the derivative action proceedings. The court noted that there was considerable disagreement between the parties about the extent of Mr Anushka’s involvement in Health & Help and about the ownership and control structure of the companies.
Med Travel was incorporated on 5 June 2012 and was described as being involved in travel agency and tour operator activities, including arranging travel and accommodation for medical tourists in Singapore and Southeast Asia. At incorporation, Mr Anushka was the sole shareholder and director on record. On 20 November 2013, Mr Anushka transferred 50% of the shares to Mr Liaskovskyi. On 13 June 2016, Mr Liaskovskyi transferred that 50% shareholding to Ms Mytsyk. Ms Mytsyk was appointed a director of Med Travel on 7 June 2018. While these documentary facts were not denied, the parties diverged sharply on their meaning and on the alleged underlying beneficial ownership arrangements.
Ms Mytsyk’s case was that Mr Anushka acted only as a “nominee shareholder and director” and held shares on behalf of Mr Liaskovskyi, the true beneficial owner. She alleged that Mr Anushka should have transferred 100% of the shares to Mr Liaskovskyi in November 2013 rather than only 50%, and that Mr Anushka forged Mr Liaskovskyi’s signature on the share transfer documents. She further alleged that Mr Anushka forged documents relating to her appointment as a director, though she later took the position that she consented to and/or ratified the appointment. Mr Anushka’s position was that Med Travel formed part of a “Family Business” together with Health & Help, and that he and Ms Mytsyk were equal partners under a “Mutual Understanding” governing how the companies would be run and how income and family expenses would be managed.
What Were the Key Legal Issues?
The High Court had to determine whether Ms Mytsyk satisfied the statutory prerequisites for obtaining leave to bring a statutory derivative action under s 216A of the Companies Act. This involved, first, the issue of locus standi: whether Ms Mytsyk fell within the statutory definition of a “complainant” and whether she could properly bring the application as a shareholder or as a “proper person” under the relevant provisions.
Second, the court had to assess whether the application met the substantive gatekeeping requirements in s 216A(3). In particular, the court addressed the “good faith” requirement in s 216A(3)(b), which requires the court to be satisfied that the complainant is acting in good faith. The court also had to consider whether the proposed derivative action “appears prima facie to be in the interests of the company” under s 216A(3)(c). These requirements are not mere formalities; they are designed to prevent derivative actions from being used as instruments of oppression, collateral attacks, or strategic litigation unrelated to the company’s interests.
Third, the court had to evaluate whether the proposed claims against Mr Anushka, as framed by Ms Mytsyk, were sufficiently coherent and credible at the leave stage to satisfy the prima facie interests threshold. While the court was not conducting a full trial, it still had to engage with the nature of the allegations and the plausibility of the asserted breaches of directors’ duties, including whether the allegations were potentially tainted by collateral purpose.
How Did the Court Analyse the Issues?
Locus standi and the capacity of the applicant formed the court’s starting point. Mr Anushka argued that Ms Mytsyk had no locus standi because she did not fall within the definition of a “complainant” under s 216A(1). He contended that she failed to identify the capacity in which she was bringing the application and that she could not show standing as a shareholder under s 216(1)(a) or as a “proper person” under s 216(1)(c). The court rejected the suggestion that Ms Mytsyk had failed to identify her capacity. It observed that her affidavit evidence and the manner in which she framed the application indicated that she was bringing the application as a complainant within the statutory scheme.
The court’s approach reflects a pragmatic view of locus standi in statutory derivative actions: while the statutory definitions matter, the court will look at substance over form to determine whether the applicant is within the class of persons empowered to seek leave. In doing so, the court ensured that the statutory derivative mechanism remains accessible to eligible complainants while still being subject to the substantive filters in s 216A(3).
Good faith under s 216A(3)(b) was the most detailed part of the analysis. The court examined whether Ms Mytsyk was acting in good faith and whether the intended derivative action was brought for a collateral purpose. Mr Anushka’s contention was that the derivative action was not genuinely aimed at protecting Med Travel’s interests but was instead part of the broader dispute between the parties, including the earlier suit S 1247 and the divorce proceedings. The court therefore scrutinised the relationship between the derivative action allegations and the ongoing litigation and ownership contest.
In evaluating good faith, the court considered the specific allegations Ms Mytsyk advanced. These allegations were grouped in the judgment’s structure: misappropriation of funds (withdrawals totalling $477,000 around 1 October 2019); forgery of “financial documents”; causing Med Travel to incur unaffordable debt by purchasing the Royal Square property; diversion of income from Med Travel to Mr Anushka’s own company; unlawful prevention of Med Travel from carrying on business; misuse of company funds for personal expenses; negligence causing penalties due to late GST payments; and related claims about the mortgage overdraft facilities and the company’s financial exposure.
The court also addressed the allegation that Mr Anushka caused Med Travel to purchase the property when it could not service the financing charges. Ms Mytsyk’s case relied on the existence of overdraft facilities granted by the mortgagee bank (RHB) and on the claim that Mr Anushka drew on those facilities to meet monthly mortgage payments, leaving the company overdrawn and at risk of further debt. The court’s analysis at the leave stage would necessarily involve assessing whether these allegations, if established, could amount to breaches of directors’ duties and whether they were not merely speculative or strategic.
Similarly, the court considered the allegation that Mr Anushka diverted income due to Med Travel, including rental income arising from the property being rented out. Ms Mytsyk alleged that tenancy arrangements provided for rent to be paid into Mr Anushka’s personal account rather than Med Travel’s account, and that while she eventually obtained a change, he allegedly reverted to the improper arrangement on multiple occasions. The court treated these allegations as relevant to whether the derivative action was genuinely directed at remedying harm to the company.
Collateral purpose and the interaction with S 1247 were central to the good faith inquiry. The court examined the dispute in S 1247, including the ownership declarations sought there. It then assessed whether the derivative action was being used to pursue ends that were not aligned with the company’s interests. The judgment’s structure indicates that the court considered each category of alleged wrongdoing and then asked whether, taken together, the intended derivative action appeared to be brought for a collateral purpose rather than for the company’s benefit.
In doing so, the court applied the principles governing good faith and the statutory threshold. The court’s reasoning reflects that good faith is assessed contextually: where there is an ongoing dispute between shareholders or between a director and a complainant, the court must be alert to the possibility that the derivative action is being deployed as a litigation tactic. However, the court also recognised that allegations of misappropriation, diversion, and unauthorised expenditure can be legitimate grounds for a derivative action even where the parties are in broader conflict.
Prima facie interests of the company under s 216A(3)(c) required a further evaluative step. The court considered whether the proposed derivative action appeared prima facie to be in Med Travel’s interests. This does not require proof at trial; rather, it requires the court to be satisfied that there is a credible basis for the claims and that the relief sought would plausibly benefit the company. The court’s analysis therefore connected the alleged breaches of directors’ duties to potential remedies for the company, such as recovery of misappropriated funds, rectification of improper transactions, and prevention of further harm.
Ultimately, the court’s reasoning demonstrates the balancing exercise inherent in s 216A: the court must prevent abuse of the derivative mechanism while ensuring that legitimate claims for breaches of directors’ duties can be pursued where the company itself may be unable or unwilling to act. The judgment’s detailed treatment of each allegation underscores that the prima facie interests inquiry is not abstract; it is grounded in the substance of the proposed claims.
What Was the Outcome?
The High Court granted leave for the statutory derivative action to proceed. In practical terms, this meant that Ms Mytsyk was permitted to bring an action in the name and on behalf of Med Travel against Mr Anushka for the alleged breaches of directors’ duties, subject to the statutory framework and the court’s leave conditions.
The effect of the decision is that the derivative action mechanism was not treated as an automatic extension of the parties’ family and ownership disputes. Instead, the court applied the statutory filters of good faith and prima facie company interests, and concluded that the application met those thresholds sufficiently to warrant leave.
Why Does This Case Matter?
It clarifies how Singapore courts apply s 216A at the leave stage. Statutory derivative actions are designed to address situations where directors may breach duties and the company is unlikely to sue itself. However, the leave requirements in s 216A(3) operate as a safeguard against collateral or abusive litigation. This case illustrates how the court scrutinises good faith and the prima facie interests of the company, particularly where the complainant and the director are involved in parallel disputes.
It highlights the importance of evidential coherence and contextual assessment. The judgment shows that courts will examine the factual matrix underlying the proposed claims, including whether the allegations are connected to genuine corporate harm. Where there is an ongoing ownership dispute or family litigation, the court will still consider whether the derivative action is genuinely aimed at protecting the company’s interests rather than advancing personal grievances.
For practitioners, it provides a roadmap for structuring derivative applications. Lawyers seeking leave under s 216A should ensure that the applicant’s standing is clearly articulated, that the application addresses good faith directly, and that the proposed causes of action are framed in a way that demonstrates prima facie benefit to the company. Conversely, directors resisting leave should focus not only on formal locus standi but also on the statutory good faith and collateral purpose concerns, supported by the broader litigation context.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), s 216A (including s 216A(3)(b) and s 216A(3)(c))
- Companies Act (Cap 50, 2006 Rev Ed), s 216 (including definitions relevant to “complainant” and “proper person”)
Cases Cited
- [2014] SGHC 147
- [2015] SGHC 14523
- [2019] SGHC 180
- [2022] SGHC 75
Source Documents
This article analyses [2022] SGHC 75 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.